Sponsored Links


Displaying ticagrelor PowerPoint Presentations

Comparing ticagrelor versus prasugrel for the treatment of ... PPT

Presentation Summary : Title: Comparing ticagrelor versus prasugrel for the treatment of patients with acute coronary syndromes: evidence from a 32,983-patient adjusted indirect comparison ...

Source : http://www.clinicaltrialresults.org/Slides/Prasugrel%20vs%20Ticagrelor.ppt

PowerPoint Presentation PPT

Presentation Summary : STEMI Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with ...

Source : http://assets.cardiosource.com/Steg_PLATO.ppt

PowerPoint Presentation PPT

Presentation Summary : Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI ...

Source : http://assets.cardiosource.com/Wallentin_PLATO.ppt

Anticoagulant/Anti-Platelet Therapy: The New Kids on The ... PPT

Presentation Summary : Accessed 2/28/11 Ticagrelor (Brilinta®) – PLATO Walletin L, et al. NEJM 2009;361(11):1045-57. Ticagrelor (Brilinta®) Walletin L, et al. NEJM 2009;361(11) ...

Source : http://www.aacn.org/wd/chapters/chapterdocs/00382581/websites/docs/%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%205%20Anticoagulation,%20Antiplatelets_%20The%20New%20Kids%20on%20the%20Block%20%20Erica%20Maceira.pps


Presentation Summary : ... Ticagrelor 180 mg loading dose, 90mg BID Clopidogrel 300-600 mg loading dose, 75 mg QD All patients received ASA 75-325 mg Wallentin, L et al NEJM 2009; ...

Source : http://www.pitt.edu/~super4/40011-41001/40131-40141.ppt

Non-Invasive Management of Non-ST Elevation (NSTE) Acute ... PPT

Presentation Summary : A Pharmacodynamic Evaluation of Switching from Ticagrelor to Prasugrel in Subjects with Stable Coronary Artery Disease: Results of the SWAP-2 Study

Source : http://www.clinicaltrialresults.org/Slides/AHA%202013/Angiolillo_SWAP-2.ppt

Aggregation on Aspirin, Aspirin + Clopidogrel, and Aspirin ... PPT

Presentation Summary : Aggregation on Aspirin, Aspirin + Clopidogrel, and Aspirin + Ticagrelor. 8 hrs post-180 mg ticagrelor load. Aggregation in 42% of pts on clopidogrel + aspirin:

Source : http://www.accelmed.org/prog/Red_Paris_Gurbel.pptx

Dual Antiplatelet Therapy - Hunter New England Health ... PPT

Presentation Summary : Outline. Clopidogrel. Limitations. Newer agents. Prasugrel. Ticagrelor. Key studies (TIMI TRITON and PLATO) Comparison. Difficult. Important differences. Discussion

Source : http://www.gardinerlibrary.com/media/Cardio2012/Dual_antiplatelet_therapy.pptx

Prasugrel in all ACS Patients! - metcardio.org PPT

Presentation Summary : Prasugrel vs ticagrelor in acute coronary syndromes. Giuseppe Biondi-Zoccai, MD. Sapienza University ofRome, Italy. giuseppe.biondizoccai@uniroma1.it

Source : http://www.metcardio.org/ppts/2013/Biondi-Zoccai_ICICEM_2013_Prasugrel_ticagrelor.pptx

Venous Thromboembolism Prophylaxis for Inpatients PPT

Presentation Summary : Venous Thromboembolism Prophylaxis for Medical Inpatients Dennis Whang 4/2/12 DSR2 Mini Lecture Objectives Recognize the morbidity and mortality with venous ...

Source : http://www.medicine.uci.edu/residency/powerpoint/VTE%20ppx.ppt

PowerPoint Presentation PPT

Presentation Summary : We suggest ticagrelor 90 mg twice daily plus low-dose aspirin over clopidogrel 75 mg daily plus low-dose aspirin (Grade 2B).

Source : http://www.chestnet.org/~/media/chesnetorg/Guidelines%20and%20Resources/Documents/Guidelines%20and%20Consensus%20Statements/20PrimSecPrevofCardiovasDis.ashx

Canadian Cardiovascular Society - Thrombosis Canada ... PPT

Presentation Summary : The strong benefit of ticagrelor over clopidogrel in patients with CKD contrasts with the lack of effect observed with clopidogrel against placebo in similar CKD ...

Source : http://www.tigc.org/getattachment/4b977ea8-0a29-44c2-9ba2-a7bed44f31f5/CKD-CCS-APT-TIG_June-16.aspx

PowerPoint Presentation PPT

Presentation Summary : Ticagrelor and its active metabolite are approximately equipotent. Transitioning from clopidogrel to ticagrelor resulted in an absolute inhibition of platelet ...

Source : http://www.palmettohealth.org/documents/Baptist%20CME/Cardiovascular%20NDU%20Palmetto%20Baptist%201%2D2013%20CWW%20updated%201%2D2%2D13.ppt

PowerPoint Presentation PPT

Presentation Summary : ... more intense P2Y12 receptor inhibition for one year with ticagrelor in comparison with clopidogrel in a broad population with ST- and non-ST-elevation ACS ...

Source : http://cardionale.org/lectures/16-antiagregants-in-acs-trusinskis/soubory/Antiagregants%20in%20ACS%20-44.ppt

FDA ACM PowerPoint Template - Food and Drug Administration PPT

Presentation Summary : Title: FDA ACM PowerPoint Template Author: Lee W. Potts Last modified by: FDA.CDER Created Date: 10/10/2000 4:11:02 PM Document presentation format

Source : http://www.fda.gov/ohrms/dockets/ac/02/slides/3849S1_01_merck.ppt

Antiplatelet Therapy for Secondary Prevention in the First ... PPT

Presentation Summary : Randomized to ticagrelor*: efficacy population N= 4,201 . Randomized to clopidogrel: efficacy population N= 4,229 . No intake of study medication: 36 patients .

Source : http://www.tigc.org/getattachment/8376d824-db46-49c2-a38e-72d34ffc490c/ACS.aspx

Slide 1 PPT

Presentation Summary : ... ticagrelor reduces cardiovascular endpoints with this benefit offset by non-procedure-related bleeding. Ticagrelor Place in Therapy Clopidogrel issue ...

Source : http://www.acha.org/AnnualMeeting/webhandouts_2012/WE2-130%20D_Sturpe.ppt

The Evolution of Antiplatelet Therapy in ACS and PCI PPT

Presentation Summary : P2Y 12 inhibitor therapy (clopidogrel, prasugrel, or ticagrelor for at least 12 months in patients receiving a stent (BMS or DES) during PCI for ACS . I. B.

Source : http://www.inosteo.org/UserFiles/File/PowerPoint/32nd%20Annual%20Winter%20Update/Saturday/Examining%20Contemporary%20Antilplatelet%20Strategies%20.Villanueva.pptx

Slide 1 PPT

Presentation Summary : Ticagrelor is the first in a new chemical class, the CPTPs, and is chemically distinct from the thienopyridines, prasugrel and clopidogrel[Husted 2006:A] ...

Source : http://www.philheart.org/43rd/images/images/caguioathrombus.ppt

Sponsored Links
If you find powerpoint presentation a copyright It is important to understand and respect the copyright rules of the author.
Please do not download if you find presentation copyright.
If you find a presentation that is using one of your presentation without permission, contact us immidiately at

© XPowerPoint.com